ALK and neoplasm: Repotrectinib is currently under investigation in a phase 1/2 multi-center, first-in-human study to define safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1, clinicaltrials.com).